Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) EPS (Basic) (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EPS (Basic) for 4 consecutive years, with -$0.21 as the latest value for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 69.57% year-over-year to -$0.21; the TTM value through Dec 2025 reached -$1.04, up 3.7%, while the annual FY2025 figure was -$1.04, 1.96% down from the prior year.
  • EPS (Basic) was -$0.21 for Q4 2025 at Day One Biopharmaceuticals, down from -$0.19 in the prior quarter.
  • The five-year high for EPS (Basic) was $0.38 in Q3 2024, with the low at -$0.72 in Q1 2024.
  • Historically, EPS (Basic) has averaged -$0.42 across 4 years, with a median of -$0.54 in 2022.
  • The largest annual shift saw EPS (Basic) soared 170.37% in 2024 before it tumbled 480.0% in 2025.
  • Over 4 years, EPS (Basic) stood at -$0.56 in 2022, then dropped by 14.29% to -$0.64 in 2023, then fell by 7.81% to -$0.69 in 2024, then surged by 69.57% to -$0.21 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.21 in Q4 2025, -$0.19 in Q3 2025, and -$0.29 in Q2 2025.